A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2009
RATIONALE: Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether lapatinib ditosylate is more effective than a placebo in killing tumor cells. PURPOSE: This randomized phase II/III trial is studying how well lapatinib ditosylate works compared to a placebo in treating patients with stage IV bladder cancer.
Epistemonikos ID: f5718d84c254a803e6e71ba727209ed460c4bc75
First added on: May 05, 2024